These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8151320)

  • 1. High-dose melphalan for multiple myeloma: long-term follow-up data.
    Cunningham D; Paz-Ares L; Gore ME; Malpas J; Hickish T; Nicolson M; Meldrum M; Viner C; Milan S; Selby PJ
    J Clin Oncol; 1994 Apr; 12(4):764-8. PubMed ID: 8151320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.
    Cunningham D; Paz-Ares L; Milan S; Powles R; Nicolson M; Hickish T; Selby P; Treleavan J; Viner C; Malpas J
    J Clin Oncol; 1994 Apr; 12(4):759-63. PubMed ID: 8151319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
    Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
    Comenzo RL; Hassoun H; Kewalramani T; Klimek V; Dhodapkar M; Reich L; Teruya-Feldstein J; Fleisher M; Filippa D; Nimer SD
    Leukemia; 2006 Feb; 20(2):345-9. PubMed ID: 16319952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
    Alvares CL; Davies FE; Horton C; Patel G; Powles R; Sirohi B; Zuha R; Gatt A; Saso R; Treleaven JG; Dearden CE; Potter MN; Ethell ME; Morgan GJ
    Br J Haematol; 2005 Jun; 129(5):607-14. PubMed ID: 15916682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
    Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [First-line treatment of severe myelomas of the young subject by high-dose melphalan].
    Harousseau JL; Milpied N; Guilhot F; Garand R; Bourhis JH
    Presse Med; 1988 Aug 27-Sep 3; 17(29):1471-4. PubMed ID: 2971190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
    Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
    Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
    Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
    Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous peripheral-blood progenitor-cell support following high-dosechemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma.
    Marit G; Faberes C; Pico JL; Boiron JM; Bourhis JH; Brault P; Bernard P; Foures C; Cony-Makhoul P; Puntous M; Vezon G; Broustet A; Girault D; Reiffers J
    J Clin Oncol; 1996 Apr; 14(4):1306-13. PubMed ID: 8648388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose melphalan with re-infusion of unprocessed, G-CSF-primed whole blood is effective and non-toxic therapy in multiple myeloma.
    Ossenkoppele GJ; Schuurhuis GJ; Jonkhoff AR; van der Hem KG; Legdeur MC; Boot-Bakker A; Westra AH; Dräger AM; Huijgens PC
    Eur J Cancer; 1996 Nov; 32A(12):2058-63. PubMed ID: 9014745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple myeloma treated with high dose intravenous melphalan.
    Selby PJ; McElwain TJ; Nandi AC; Perren TJ; Powles RL; Tillyer CR; Osborne RJ; Slevin ML; Malpas JS
    Br J Haematol; 1987 May; 66(1):55-62. PubMed ID: 3593657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeat administration of high dose melphalan in relapsed myeloma.
    Mansi JL; Cunningham D; Viner C; Ellis E; Meldrum M; Milan S; Gore M
    Br J Cancer; 1993 Nov; 68(5):983-7. PubMed ID: 8217614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up after high-dose therapy for high-risk multiple myeloma.
    Barlogie B; Jagannath S; Naucke S; Mattox S; Bracy D; Crowley J; Tricot G; Alexanian R
    Bone Marrow Transplant; 1998 Jun; 21(11):1101-7. PubMed ID: 9645572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma.
    McElwain TJ; Gore ME; Meldrum M; Viner C; Judson IR; Malpas JS
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():109-12. PubMed ID: 2697419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-intensive therapy in high-risk multiple myeloma.
    Harousseau JL; Milpied N; Laporte JP; Collombat P; Facon T; Tigaud JD; Casassus P; Guilhot F; Ifrah N; Gandhour C
    Blood; 1992 Jun; 79(11):2827-33. PubMed ID: 1350228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
    Moreau P; Fiere D; Bezwoda WR; Facon T; Attal M; Laporte JP; Colombat P; Haak HL; Monconduit M; Lockhorst H; Girault D; Harousseau JL
    J Clin Oncol; 1997 Feb; 15(2):660-6. PubMed ID: 9053491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-risk multiple myeloma treated with high-dose melphalan.
    Lokhorst HM; Meuwissen OJ; Verdonck LF; Dekker AW
    J Clin Oncol; 1992 Jan; 10(1):47-51. PubMed ID: 1727925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.